The systemic hormonal preparations market (excluding sex hormones and insulins) in Canada is witnessing a steady growth from 2024 onwards, with the forecasted sales increasing from $543.8 million in 2024 to $584.7 million by 2028. Since the year-on-year variation indicates a stable increase, the Compound Annual Growth Rate (CAGR) over the next five years suggests consistent expansion. The value for 2023 was slightly lower as market dynamics evolve with increasing demand and innovation.

Future trends to watch for in this market include:

Technological advancements in hormonal therapies that may boost market penetration.
Regulatory changes impacting the approval and commercialization of new hormonal drugs.
Increasing awareness and diagnosis rates of hormone-related conditions contributing to market growth.